Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Hones In On Denosumab Sales And Payer Strategies Ahead Of Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech estimates 500 to 1,000 sales reps will be needed to commercialize the osteoporosis injectable in the U.S.

You may also be interested in...



Denosumab Uptake Could Depend On Abating Physicians’ Financial Risk

If denosumab is approved, Amgen may need to provide physicians with a shield against the financial risk of stocking the injectable osteoporosis treatment in their offices

Amgen’s Positive Denosumab Pivotal Trial Reduces Overhangs For Firm

Big biotech needs the potential $2.4 billion analysts estimate the bone-building drug could bring by 2016.

Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research

The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.

Topics

UsernamePublicRestriction

Register

PS066992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel